• Solid progress in results:
o Operating profit: +8.95% to €50.26 million.
o Net profit: +25.97% to €41.15 million.
o Basic Earnings per Share: +27.78% to €2.60.
• Dividend proposed for the 2021 financial year: €1.05 per share (+10.5%).
• The Group maintains its level of profitability (26.13% vs 27.16% in 2020) and confirms the agility and scalability of its ecosystem in the integration of new activities and/or professions (in 2021, creation of PHARMAGEST SERVIZI, takeover of the assets of the Wholesalers-Distributors part of ATHESIA, acquisition of PROKOV EDITIONS).
• The Group maintains its ambitions for profitable growth, development and investments in 2022.
Project to change the name of the Pharmagest Group to become the EQUASENS Group.
The full press release is online on the Pharmagest website: www.pharmagest.com
Finance section / Press releases
Follow Pharmagest on Twitter: @Pharmagest, Linkedin and Facebook